Did Atozet impact on sales decrease of Vytorin, resulting winning of Lipitor in the first half?

Although MSD Korea has pressured Pfizer Korea’s ‘Lipitor(generic name: atorvastatin)’ by launching ‘Atozet,’ a hyperlipidemia treatment adding ‘atorvastatin’ in ‘ezetimibe,’ this April, it was not able to make a successful record, which led a lean towards Lipitor.

Despite the launch of Atozet, Lipitor’s prescriptions were increased to KRW 62.1 billion in the first half from KRW 59.7 billion in...